Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||
Cash And Cash Equivalents At Carrying Value | 62 | 6 | 5 | 5 | |||||
Assets Current | |||||||||
Assets Current | 63 | 9 | 5 | 6 | |||||
Restricted Cash Current | 0 | 0 | 0 | 0 | |||||
Unbilled Contracts Receivable | - | - | 0 | - | |||||
Prepaid Expense And Other Assets Current | 1 | 2 | 0 | 1 | |||||
Property Plant And Equipment Net | - | - | 0 | 0 | |||||
Operating Lease Right Of Use Asset | - | - | 0 | 0 | |||||
Assets | 63 | 9 | 5 | 6 | |||||
Liabilities And Stockhold… | |||||||||
Accounts Payable Current | 3 | 3 | 3 | 3 | |||||
Accrued Liabilities Current | 2 | 1 | 2 | 2 | |||||
Long Term Debt Current | 0 | 0 | 1 | 3 | |||||
Liabilities Current | |||||||||
Liabilities Current | 17 | 16 | 17 | 23 | |||||
Deposit Liabilities Accrued Interest | 0 | 0 | 0 | - | |||||
Operating Lease Liability Current | - | - | 0 | 0 | |||||
Derivative Liabilities Current | - | - | 0 | 0 | |||||
Long Term Debt Noncurrent | - | - | 0 | 3 | |||||
Operating Lease Liability Noncurrent | - | - | 0 | 0 | |||||
Liabilities | - | - | 17 | 26 | |||||
Preferred Stock Value | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital Common Stock | 355 | 297 | 289 | 268 | |||||
Retained Earnings Accumulated Deficit | -309 | -304 | -301 | -289 | |||||
Stockholders Equity | 46 | -8 | -12 | -20 | |||||
Liabilities And Stockholders Equity | 63 | 9 | 5 | 6 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | |||||
Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | |||||
Common Stock Shares Authorized | 100 | 500 | 500 | 500 | |||||
Common Stock Shares Issued | 4 | 5 | 5 | 3 | |||||
Shares Outstanding | 4 | 5 | 5 | 2 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | - | - | - | - | - | - | 184.62% | - | - | - | - | - |
| 2025 | - | - | - | - | - | - | - | - | - | 83500.00% | 130000.00% | 563536.35% |
| 2024 | -19.49% | 0.00% | -27.12% | - | - | - | - | - | - | - | - | - |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Eloxx Pharmaceuticals, Inc. (ELOX) — SEC Financial Statements & Analysis
Eloxx Pharmaceuticals, Inc. (ELOX) is a biological products, (no diagnostic substances) company, incorporated in DE. Eloxx Pharmaceuticals, Inc. trades on Nasdaq as: ELOX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Eloxx Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of 0.37x, a Price-to-Book (P/B) ratio of 2.03x (TTM), at a market cap of $94.23M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- 0.37x
- P/B TTM
- 2.03x
- Market Cap
- $94.23M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Eloxx Pharmaceuticals, Inc. in?
Eloxx Pharmaceuticals, Inc. (ELOX) operates in the Biological Products, (No Diagnostic Substances) industry.
What is ELOX's market cap?
Eloxx Pharmaceuticals, Inc. (ELOX) has a market capitalization of $94.23M as of 2026-06-30.
What exchange does ELOX trade on?
Eloxx Pharmaceuticals, Inc. (ELOX) trades on the Nasdaq.
Where is Eloxx Pharmaceuticals, Inc. incorporated?
Eloxx Pharmaceuticals, Inc. is incorporated in DE.